Compare VanEck Uranium & Nuclear ETF (NLR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Uranium & Nuclear ETF vs Sana Biotechnology Inc — how do they compare? VanEck Uranium & Nuclear ETF trades at $122.23, while Sana Biotechnology Inc trades at $3.24 (market cap $1.03B). The key difference: VanEck Uranium & Nuclear ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| NLR | SANA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $164.37 | $5.92 |
52-Week Low | $102.70 | $2.68 |
Market Cap | — | $1.03B |
Enterprise Value | — | $946.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Uranium & Nuclear ETF
VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.
Read more on NLR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
